

ASTRAZENECA PLC

Interim Financial Statements

30 September 2006

Registered number: 2723534



ASTRAZENECA PLC

PROFIT AND LOSS ACCOUNT

for the nine months ended 30 September 2006

	Notes	30 September 2006 \$m	31 December 2005 \$m
Turnover		-	-
Operating costs		(6)	(8)
Operating loss		(6)	(8)
Income from shares in subsidiary undertakings		-	1,183
(Loss)/Profit on ordinary activities before interest		(6)	1,175
Net interest and exchange losses	2	(5)	(20)
(Loss)/Profit on ordinary activities before taxation		(11)	1,155
Taxation		(21)	113
Net (Loss)/Profit for the year		(32)	1,268
Dividends to Shareholders	3	(2,217)	(1,676)
Loss retained for the year		(2,249)	(408)

There are no gains or losses other than those reported above (2005 nil).

ASTRAZENECA PLC

BALANCE SHEET

	Notes	30 September 2006 \$m	31 December 2005 \$m
Fixed assets			
Fixed asset investments	4	22,411	24,856
Current assets			
External debtors - other		11	27
Debtors – amounts owed by subsidiaries		96	340
		107	367
Total assets		22,518	25,223
Creditors due within one year			
Short-term borrowings		(10)	(5)
Other creditors		(35)	(5)
Amounts owed to subsidiaries		(1,543)	(10)
		(1,588)	(20)
Net current (liabilities)/assets		(1,481)	347
Total assets less current liabilities		20,930	25,203
Creditors due after more than one year			
Loans		(1,030)	(1,030)
Net assets		19,900	24,173
Capital and reserves			
Called-up share capital	5	388	395
Share premium account	6	1,620	692
Capital redemption reserve	6	66	53
Other reserves	6	1,841	1,841
Profit and loss account	6	15,985	21,192
Shareholders' funds - equity interests	7	19,900	24,173

The interim financial statements on pages 1 to 5 were approved by the Board of directors on 25 October 2006 and were signed on its behalf by:



David R Brennan
Director



Jonathan Symonds
Director

ASTRAZENECA PLC

NOTES RELATING TO THE FINANCIAL STATEMENTS

1 Basis of presentation of financial information

The AstraZeneca PLC interim financial statements are presented in accordance with the accounting policies set out in the 2005 annual accounts.

These interim financial statements do not constitute statutory accounts of the Company within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2005 have been filed with the Registrar of Companies. The auditor's report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985.

2 Net interest and exchange losses

	30 September 2006 \$m	31 December 2005 \$m
Interest payable and similar charges		
Payable to subsidiary undertakings	(17)	(20)
External interest payable	(30)	(41)
Net exchange losses	(4)	(20)
	(51)	(81)
Interest receivable and similar income		
Receivable from subsidiary undertakings	46	61
Net interest and exchange losses	(5)	(20)

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

3 Dividends to shareholders

	30 Sep 2006 Per Share	31 Dec 2005 Per Share	30 Sep 2006 \$m	31 Dec 2005 \$m
2 nd interim/final	\$0.92	\$0.645	1,453	1,061
1 st interim	\$0.49	\$0.38	764	615
	\$1.41	\$1.025	2,217	1,676

4 Fixed Asset Investments

	Shares \$m	Loans \$m	Total \$m
Cost			
At beginning of period	6,715	18,141	24,856
Repayment of loan	-	(2,445)	(2,445)
At end of period	6,715	15,696	22,411

5 Called-up share capital

	Authorised	Allotted, called-up and fully paid	
	30 Sep 2006 \$m	30 Sep 2006 \$m	31 Dec 2005 \$m
Ordinary Shares (\$0.25 each)	388	388	395
Unissued Ordinary Shares (\$0.25 each)	212	-	-
Redeemable Preference Shares (£50,000)	-	-	-
	600	388	395

The movements in share capital during the period can be summarised as follows:

	No. shares (millions)	\$m
At beginning of period	1,581	395
Issue of shares	22	6
Repurchase of shares	(52)	(13)
At end of period	1,551	388

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

6 Reserves

	Share Premium Account \$m	Capital Redemption Reserve \$m	Other Reserves \$m	Profit and Loss Account \$m	Total 30 Sep 2006 \$m	Total 31 Dec 2005 \$m
At beginning of period	692	53	1,841	21,192	23,778	27,028
Net (loss)/profit for the period	-	-	-	(32)	(32)	1,268
Dividends	-	-	-	(2,217)	(2,217)	(1,676)
Share repurchase	-	13	-	(2,958)	(2,945)	(2,984)
Share premiums	928	-	-	-	928	142
At end of period	1,620	66	1,841	15,985	19,512	23,778
Distributable reserves at end of period	-	-	1,661	1,563	3,224	5,058

At 30 September 2006 \$14,422m (31 December 2005: \$16,867m) of the profit and loss account reserve was not available for distribution. The majority of this non-distributable amount relates to profit arising on the sale of Astra AB to a subsidiary in 1999, which becomes distributable as the underlying receivable is settled in cash. During the nine months \$2,445m of the profit was released by repayment. Subsequent to the period end a further \$3,293m was repaid on 20 October 2006, resulting in additional distributable reserves not included in the figures above. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999.

7 Reconciliation of movements in shareholders' funds

	30 September 2006 \$m	31 December 2005 \$m
Net (losses)/gains for the financial period	(32)	1,268
Dividends	(2,217)	(1,676)
	(2,249)	(408)
Issue of AstraZeneca Ordinary Shares	934	143
Repurchase of AstraZeneca Ordinary Shares	(2,958)	(3,001)
Net reduction in shareholders' funds	(4,273)	(3,266)
Shareholders' funds at beginning of period	24,173	27,439
Shareholders' funds at end of period	19,900	24,173